Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial

Mette Bjerre; Jørgen Hilden; Jens Kastrup; Maria Skoog; Jørgen F Hansen; Hans J Kolmos; Gorm B Jensen; Erik Kjøller; Per Winkel; Allan Flyvbjerg; Christian Gluud; CLARICOR Trial Group

doi:10.3109/00365513.2014.930510

Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial

Mette Bjerre, Jørgen Hilden, Jens Kastrup, Maria Skoog, Jørgen F Hansen, Hans J Kolmos, Gorm B Jensen, Erik Kjøller, Per Winkel, Allan Flyvbjerg, Christian Gluud, CLARICOR Trial Group

18 Citations (Scopus)

Abstract

Objectives. To elucidate the prognostic power of serum osteoprotegerin (OPG) in patients with stable coronary artery disease (CAD). Methods. Serum OPG levels were measured in the CLARICOR trial cohort of 4063 patients with stable CAD on blood samples drawn at randomization. The follow-up was 2.6 years for detailed cardiovascular events and 6 years for all-cause mortality. Results. OPG levels were significantly increased in non-survivors (21%) compared to survivors (median [quartiles] 2092 ng/L [1636; 2800] compared to 1695 ng/L [1322; 2193, p < 0.0001]). The 2.6-year follow-up showed that OPG adds to the prediction of both cardiovascular and all-cause mortality in combination with clinical risk factors (HR [one log₁₀ unit increase] 6.1 [95% CI 2.4-15.6, p = 0.0001]) and HR 6.5 [95% CI 3.4-12.5, p < 0.0001], respectively). Similar, in the 6-year follow-up, OPG was found to be a strong predictor for all-cause mortality. Importantly, OPG remained an independent predictor of mortality even after adjustment for both clinical and conventional cardiovascular risk markers (HR 2.5 [95% CI 1.6-3.9, p < 0.0001]). Conclusions. Serum OPG has a long-lasting independent predictive power as to all-cause mortality and cardiovascular death in patients with stable CAD.

Original language	English
Journal	Scandinavian Journal of Clinical & Laboratory Investigation
Volume	74
Issue number	8
Pages (from-to)	657-664
Number of pages	8
ISSN	0036-5513
DOIs	https://doi.org/10.3109/00365513.2014.930510
Publication status	Published - 1 Nov 2014

Access to Document

10.3109/00365513.2014.930510

Cite this

Bjerre, M., Hilden, J., Kastrup, J., Skoog, M., Hansen, J. F., Kolmos, H. J., Jensen, G. B., Kjøller, E., Winkel, P., Flyvbjerg, A., Gluud, C., & CLARICOR Trial Group (2014). Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial. Scandinavian Journal of Clinical & Laboratory Investigation, 74(8), 657-664. https://doi.org/10.3109/00365513.2014.930510

Bjerre, M, Hilden, J, Kastrup, J, Skoog, M, Hansen, JF, Kolmos, HJ, Jensen, GB, Kjøller, E, Winkel, P, Flyvbjerg, A, Gluud, C & CLARICOR Trial Group 2014, 'Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 74, no. 8, pp. 657-664. https://doi.org/10.3109/00365513.2014.930510

@article{5e63e5d93fb74239b3a0fc0b40ff1c5c,

title = "Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial",

abstract = "Objectives. To elucidate the prognostic power of serum osteoprotegerin (OPG) in patients with stable coronary artery disease (CAD). Methods. Serum OPG levels were measured in the CLARICOR trial cohort of 4063 patients with stable CAD on blood samples drawn at randomization. The follow-up was 2.6 years for detailed cardiovascular events and 6 years for all-cause mortality. Results. OPG levels were significantly increased in non-survivors (21%) compared to survivors (median [quartiles] 2092 ng/L [1636; 2800] compared to 1695 ng/L [1322; 2193, p < 0.0001]). The 2.6-year follow-up showed that OPG adds to the prediction of both cardiovascular and all-cause mortality in combination with clinical risk factors (HR [one log10 unit increase] 6.1 [95% CI 2.4-15.6, p = 0.0001]) and HR 6.5 [95% CI 3.4-12.5, p < 0.0001], respectively). Similar, in the 6-year follow-up, OPG was found to be a strong predictor for all-cause mortality. Importantly, OPG remained an independent predictor of mortality even after adjustment for both clinical and conventional cardiovascular risk markers (HR 2.5 [95% CI 1.6-3.9, p < 0.0001]). Conclusions. Serum OPG has a long-lasting independent predictive power as to all-cause mortality and cardiovascular death in patients with stable CAD.",

author = "Mette Bjerre and J{\o}rgen Hilden and Jens Kastrup and Maria Skoog and Hansen, {J{\o}rgen F} and Kolmos, {Hans J} and Jensen, {Gorm B} and Erik Kj{\o}ller and Per Winkel and Allan Flyvbjerg and Christian Gluud and {CLARICOR Trial Group}",

year = "2014",

month = nov,

day = "1",

doi = "10.3109/00365513.2014.930510",

language = "English",

volume = "74",

pages = "657--664",

journal = "Scandinavian Journal of Clinical & Laboratory Investigation",

issn = "0036-5513",

publisher = "Taylor & Francis",

number = "8",

}

TY - JOUR

T1 - Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease

T2 - The CLARICOR trial

AU - Bjerre, Mette

AU - Hilden, Jørgen

AU - Kastrup, Jens

AU - Skoog, Maria

AU - Hansen, Jørgen F

AU - Kolmos, Hans J

AU - Jensen, Gorm B

AU - Kjøller, Erik

AU - Winkel, Per

AU - Flyvbjerg, Allan

AU - Gluud, Christian

AU - CLARICOR Trial Group

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Objectives. To elucidate the prognostic power of serum osteoprotegerin (OPG) in patients with stable coronary artery disease (CAD). Methods. Serum OPG levels were measured in the CLARICOR trial cohort of 4063 patients with stable CAD on blood samples drawn at randomization. The follow-up was 2.6 years for detailed cardiovascular events and 6 years for all-cause mortality. Results. OPG levels were significantly increased in non-survivors (21%) compared to survivors (median [quartiles] 2092 ng/L [1636; 2800] compared to 1695 ng/L [1322; 2193, p < 0.0001]). The 2.6-year follow-up showed that OPG adds to the prediction of both cardiovascular and all-cause mortality in combination with clinical risk factors (HR [one log10 unit increase] 6.1 [95% CI 2.4-15.6, p = 0.0001]) and HR 6.5 [95% CI 3.4-12.5, p < 0.0001], respectively). Similar, in the 6-year follow-up, OPG was found to be a strong predictor for all-cause mortality. Importantly, OPG remained an independent predictor of mortality even after adjustment for both clinical and conventional cardiovascular risk markers (HR 2.5 [95% CI 1.6-3.9, p < 0.0001]). Conclusions. Serum OPG has a long-lasting independent predictive power as to all-cause mortality and cardiovascular death in patients with stable CAD.

AB - Objectives. To elucidate the prognostic power of serum osteoprotegerin (OPG) in patients with stable coronary artery disease (CAD). Methods. Serum OPG levels were measured in the CLARICOR trial cohort of 4063 patients with stable CAD on blood samples drawn at randomization. The follow-up was 2.6 years for detailed cardiovascular events and 6 years for all-cause mortality. Results. OPG levels were significantly increased in non-survivors (21%) compared to survivors (median [quartiles] 2092 ng/L [1636; 2800] compared to 1695 ng/L [1322; 2193, p < 0.0001]). The 2.6-year follow-up showed that OPG adds to the prediction of both cardiovascular and all-cause mortality in combination with clinical risk factors (HR [one log10 unit increase] 6.1 [95% CI 2.4-15.6, p = 0.0001]) and HR 6.5 [95% CI 3.4-12.5, p < 0.0001], respectively). Similar, in the 6-year follow-up, OPG was found to be a strong predictor for all-cause mortality. Importantly, OPG remained an independent predictor of mortality even after adjustment for both clinical and conventional cardiovascular risk markers (HR 2.5 [95% CI 1.6-3.9, p < 0.0001]). Conclusions. Serum OPG has a long-lasting independent predictive power as to all-cause mortality and cardiovascular death in patients with stable CAD.

U2 - 10.3109/00365513.2014.930510

DO - 10.3109/00365513.2014.930510

M3 - Journal article

C2 - 25026506

SN - 0036-5513

VL - 74

SP - 657

EP - 664

JO - Scandinavian Journal of Clinical & Laboratory Investigation

JF - Scandinavian Journal of Clinical & Laboratory Investigation

IS - 8

ER -

Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial

Abstract

Access to Document

Fingerprint

Cite this